퀀타매트릭스
Financials
Valuation Metrics
퀀타매트릭스's Market Cap is ₩467B. At end of 2025 it was ₩964B. Ranked #1784 of 2,436 in KR market (top 73%), #1085 of 1,649 on KOSDAQ (top 66%), #195 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 83%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 46.71B KRW | KR#1,784/2,436 Sec#195/234 |
| Revenue | 3.40B KRW | KR#2,371/2,436 Sec#206/234 |
| Net Income | -19.98B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 47.87B KRW | KR#2,204/2,436 Sec#200/234 |
| Net Assets | 35.90B KRW | KR#2,091/2,436 Sec#180/234 |
| Employees | 91 | KR#1,698/2,436 Sec#132/234 |
| Value | ||
| P/B | 1.30x | KR#1,698/2,436 Sec#119/234 |
| P/S | 13.75x | KR#2,306/2,436 Sec#170/234 |
| FCF Yield | -33.41% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -55.66% | KR#2,285/2,436 Sec#203/234 |
| ROA | -41.74% | KR#2,346/2,436 Sec#215/234 |
| Op. Margin | -465.42% | KR#2,375/2,436 Sec#209/234 |
| Revenue Growth | -28.69% | KR#2,158/2,436 Sec#196/234 |
| Financial Health | ||
| Debt Ratio | 133.35% | KR#914/2,436 Sec#107/234 |
| Total Debt | 7.62B KRW | KR#1,699/2,436 Sec#159/234 |
| FCF | -15.61B KRW | KR#1,838/2,436 Sec#170/234 |
| Cash | 13.00B KRW | KR#1,512/2,436 Sec#114/234 |
| Current Ratio | 4.12x | KR#393/2,436 Sec#68/234 |
| Performance | ||
| 1Y Return | -44.50% | KR#1,952/2,436 Sec#174/234 |
| 1M Return | -8.48% | KR#1,668/2,436 Sec#168/234 |
| From 52W High | -59.37% | KR#1,680/2,436 Sec#141/234 |
| 1Y MDD | -61.99% | KR#1,528/2,436 Sec#122/234 |
| Trading | ||
| Volume | 26,781 shares | KR#1,721/2,436 Sec#174/234 |
| Foreign Own. | 18.76% | KR#245/2,436 Sec#12/234 |
| Per Share | ||
| EPS | -1,038 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,783 KRW | KR#2,090/2,436 Sec#174/234 |
Company Info
Established in 2010 and listed on KOSDAQ in 2020, this company specializes in in vitro diagnostic medical devices. It develops microbial diagnostic technology-based testing systems (dRAST, QDST), molecular immunology platforms (QMAP), and automation equipment (QMIA), which are sold to advanced general hospitals both domestically and internationally. The company is also developing the uCIA system and pursuing the commercialization of the QPLEX Alz plus Assay kit for early diagnosis of Alzheimer's disease. Quantamatrix, established in 2010, is headquartered in Seoul Metropolitan City, Geumcheon-gu.